TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02583828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5 mg
Study: NCT05331872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cell infusion
Description: Human umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis
Study: NCT02162082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent or scaffold
Description: implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
Study: NCT05960669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D model guided secondary resection
Description: A prostate model was 3D printed from preoperative pelvic MRI data and used during robot-assisted radical prostatectomy to mark a positive surgical margin and guide secondary resection.
Study: NCT00033540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
Study: NCT02092142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q fever Vaccine
Description: Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
Study: NCT04265027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg BIA 9 1067
Description: Hard Capsule; Oral
Study: NCT00033540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m\^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
Study: NCT00873379

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: half a white placebo tablet
Study: NCT03366103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib
Description: Given PO
Study: NCT02272751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
Study: NCT01371149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface parasternal electromyography (EMG) set up
Description: Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
Study: NCT04265027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg BIA9 1067
Description: Hard Capsule; Oral
Study: NCT04753554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ORI group
Description: The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
Study: NCT04265027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Ongentys
Description: Hard Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Ongentys
Description: Hard Capsule; Oral
Study: NCT01804413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegvisomant
Description: Pegvisomant 1 mg/kg injection 3 days before the glucagon test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: 0.1-0.15 units/kg
Study: NCT04753554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORI group
Description: The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: In this patient group oxygenation will be managed as usual, using blood gas analysis.
Study: NCT02822131

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: sodium phosphate

Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer, sodium bicarbonate, sodium chloride
Study: NCT01361074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In Vivo Exposure for Animal Phobia following Öst´s guidelines
Description: In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Exposure for Animal Phobia following Öst´s guidelines
Description: Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli.
Study: NCT01804413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: 0.1-0.15 units/kg
Study: NCT04832906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Oral Tablet
Description: A selective progesterone receptor modulator (SPRM), as a medical line of treatment for uterine fibroids. Due to its selective anti-proliferative and pro-apoptotic action, Ulipristal Acetate (UA) is assumed to be effective in reducing abnormal uterine bleeding (AUB) and fibroid size.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery embolization
Description: Selective embolization of uterine arteries bilaterally, using polyvinyl alcohol (PVA) particles administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected.
Study: NCT02531633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
Study: NCT01050374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albendazole + praziquantel
Description: albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
Study: NCT01050374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebendazole + praziquantel
Description: mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
Study: NCT02531633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match sirukumab
Description: Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
Study: NCT03265756

Intervention type: DEVICE
Intervention: Multimometer
Description: A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
Study: NCT02531633

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match sirukumab
Description: Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
Study: NCT03647111

Intervention type: DRUG
Intervention: Crizotinib
Description: Crizotinib 250mg po bid
Study: NCT01133275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone therapy for 6 cycles (24 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide therapy for 6 cycles (24 weeks).
Study: NCT02531633

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
Study: NCT00048815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Established Selective Serotonin Reuptake Inhibitor antidepressant
Study: NCT00048815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort
Description: Natural extract from the St. John's Wort plant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo pill
Study: NCT01028716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo PBSC
Study: NCT01028716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation (TBI)
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
Study: NCT03625791

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 1 tube with 4 ml of blood per patient
Study: NCT04284618

Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of standardized and off axis view radiographs
Description: Radiographic assessment of hallux valgus interphalangeus angles is performed on preoperative standing anteroposterior and on off axis view radiographs. These radiographs are taken by equalizing the hyperpronation of the greater toe.
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
Study: NCT03413098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal CPAP mask
Description: Investigative Nasal Mask to be used for OSA therapy
Study: NCT04338724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1002
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Study: NCT03694392

Intervention type: BIOLOGICAL
Intervention: Flublok Quadrivalent
Description: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.

Intervention type: BIOLOGICAL
Intervention: Standard Dose Inactivated Influenza Vaccine (SD-IIV)
Description: For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
Study: NCT00495521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Aminosalicylic acid extended release granules
Description: Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4-Aminosalicylic acid extended release granules
Description: Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
Study: NCT03509493

Intervention type: DIAGNOSTIC_TEST
Intervention: FibriCheck
Description: Digital health application

Intervention type: DIAGNOSTIC_TEST
Intervention: FibriCheck
Description: Digital health application

Intervention type: DIAGNOSTIC_TEST
Intervention: FibriCheck
Description: Digital health application
Study: NCT00224055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ferric Gluconate Complex in Sucrose Injection
Description: Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets
Description: ferrous sulfate, 325 mg oral, three times daily for 6 weeks
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
Study: NCT03509493

Intervention type: DIAGNOSTIC_TEST
Intervention: FibriCheck
Description: Digital health application
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
Study: NCT03509493

Intervention type: DIAGNOSTIC_TEST
Intervention: FibriCheck
Description: Digital health application

Intervention type: DIAGNOSTIC_TEST
Intervention: FibriCheck
Description: Digital health application
Study: NCT01154283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)
Description: Noninvasive positive airway pressure ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)
Description: Noninvasive positive airway pressure ventilation
Study: NCT00042432

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cinacalcet (AMG 073)
Description: Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet (AMG 073)
Description: Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.